Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment

A Correction to this article was published on 02 March 2021

This article has been updated

Abstract

Mechanisms for breast cancer metastasis remain unclear. Whether truncated glioma-associated oncogene homolog 1 (TGLI1), a transcription factor known to promote angiogenesis, migration and invasion, plays any role in metastasis of any tumor type has never been investigated. In this study, results of two mouse models of breast cancer metastasis showed that ectopic expression of TGLI1, but not GLI1, promoted preferential metastasis to the brain. Conversely, selective TGLI1 knockdown using antisense oligonucleotides led to decreased breast cancer brain metastasis (BCBM) in vivo. Immunohistochemical staining showed that TGLI1, but not GLI1, was increased in lymph node metastases compared to matched primary tumors, and that TGLI1 was expressed at higher levels in BCBM specimens compared to primary tumors. TGLI1 activation is associated with a shortened time to develop BCBM and enriched in HER2-enriched and triple-negative breast cancers. Radioresistant BCBM cell lines and specimens expressed higher levels of TGLI1, but not GLI1, than radiosensitive counterparts. Since cancer stem cells (CSCs) are radioresistant and metastasis-initiating cells, we examined TGLI1 for its involvement in breast CSCs and found TGLI1 to transcriptionally activate stemness genes CD44, Nanog, Sox2, and OCT4 leading to CSC renewal, and TGLI1 outcompetes with GLI1 for binding to target promoters. We next examined whether astrocyte-priming underlies TGLI1-mediated brain tropism and found that TGLI1-positive CSCs strongly activated and interacted with astrocytes in vitro and in vivo. These findings demonstrate, for the first time, that TGLI1 mediates breast cancer metastasis to the brain, in part, through promoting metastasis-initiating CSCs and activating astrocytes in BCBM microenvironment.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Change history

References

  1. 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA. 2018;68:7–30.

    PubMed  PubMed Central  Google Scholar 

  2. 2.

    Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, et al. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017;8:27990–6.

    PubMed  PubMed Central  Google Scholar 

  3. 3.

    Ekici K, Temelli O, Dikilitas M, Halil Dursun I, Bozdag Kaplan N, Kekilli E. Survival and prognostic factors in patients with brain metastasis: Single center experience. J BUON. 2016;21:958–63.

    PubMed  PubMed Central  Google Scholar 

  4. 4.

    Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K, et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat. 2014;147:103–12.

    PubMed  Google Scholar 

  5. 5.

    Cao X, Geradts J, Dewhirst MW, Lo HW. Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells. Oncogene. 2012;31:104–15.

    CAS  PubMed  Google Scholar 

  6. 6.

    Carpenter RL, Paw I, Zhu H, Sirkisoon S, Xing F, Watabe K, et al. The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis. Oncotarget. 2015;6:22653–65.

    PubMed  PubMed Central  Google Scholar 

  7. 7.

    Han W, Carpenter RL, Lo H-W. TGLI1 upregulates expression of VEGFR2 and VEGF-A, leading to a robust VEGF-VEGFR2 autocrine loop and cancer cell growth. Cancer Hallm. 2013;1:28–37.

    Google Scholar 

  8. 8.

    Lo HW, Zhu H, Cao X, Aldrich A, Ali-Osman F. A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion. Cancer Res. 2009;69:6790–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Rimkus TK, Carpenter RL, Sirkisoon S, Zhu D, Pasche BC, Chan MD, et al. Truncated glioma-associated oncogene homolog 1 (tGLI1) mediates mesenchymal glioblastoma via transcriptional activation of CD44. Cancer Res. 2018;78:2589–2600.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Zhu H, Carpenter RL, Han W, Lo HW. The GLI1 splice variant TGLI1 promotes glioblastoma angiogenesis and growth. Cancer Lett. 2014;343:51–61.

    CAS  PubMed  Google Scholar 

  11. 11.

    Sirkisoon SR, Carpenter RL, Rimkus T, Anderson A, Harrison A, Lange AM, et al. Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene. 2018;37:2502–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Fan YH, Ding J, Nguyen S, Liu XJ, Xu G, Zhou HY, et al. Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells. Oncogene. 2015;35:116.

    PubMed  Google Scholar 

  13. 13.

    Di Mauro C, Rosa R, D’Amato V, Ciciola P, Servetto A, Marciano R, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017;116:1425.

    PubMed  PubMed Central  Google Scholar 

  14. 14.

    Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013;73:4885–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Dahmane N, Sánchez P, Gitton Y, Palma V, Sun T, Beyna M, et al. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development. 2001;128:5201–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Wang T, Shigdar S, Gantier MP, Hou Y, Wang L, Shamaileh HA, et al. Cancer stem cell targeted therapy: progress amid controversies. Oncotarget. 2015;6:44191–206.

  17. 17.

    Lorger M, Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol. 2010;176:2958–71.

    PubMed  PubMed Central  Google Scholar 

  18. 18.

    Wang Z, Oron E, Nelson B, Razis S, Ivanova N. Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell. 2012;10:440–54.

    CAS  PubMed  Google Scholar 

  19. 19.

    Wang L, Zuo X, Xie K, Wei D. The role of CD44 and cancer stem cells. Methods Mol Biol. 2018;1692:31–42.

    CAS  PubMed  Google Scholar 

  20. 20.

    Bora-Singhal N, Perumal D, Nguyen J, Chellappan S. Gli1-mediated regulation of Sox2 facilitates self-renewal of stem-like cells and confers resistance to EGFR Inhibitors in non–small cell lung cancer. Neoplasia. 2015;17:538–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Li Q, Lex RK, Chung H, Giovanetti SM, Ji Z, Ji H, et al. The pluripotency factor NANOG binds to GLI proteins and represses hedgehog-mediated transcription. J Biol Chem. 2016;291:7171–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Huang D, Wang Y, Xu L, Chen L, Cheng M, Shi W, et al. GLI2 promotes cell proliferation and migration through transcriptional activation of ARHGEF16 in human glioma cells. J Exp Clin cancer Res. 2018;37:247.

    PubMed  PubMed Central  Google Scholar 

  23. 23.

    Komada M, Saitsu H, Shiota K, Ishibashi M. Expression of Fgf15 is regulated by both activator and repressor forms of Gli2 in vitro. Biochem Biophys Res Commun. 2008;369:350–6.

    CAS  PubMed  Google Scholar 

  24. 24.

    Wang JX, Zhou JF, Huang FK, Zhang L, He QL, Qian HY, et al. GLI2 induces PDGFRB expression and modulates cancer stem cell properties of gastric cancer. Eur Rev Med Pharmacol Sci. 2017;21:3857–65.

    PubMed  PubMed Central  Google Scholar 

  25. 25.

    Zucchi I, Mento E, Kuznetsov VA, Scotti M, Valsecchi V, Simionati B, et al. Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis. PNAS. 2004;101:18147–52.

    CAS  PubMed  Google Scholar 

  26. 26.

    Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005–1009.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JGM, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108–14.

    CAS  PubMed  Google Scholar 

  28. 28.

    Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov Jill P, Tamayo P. The molecular signatures database hallmark gene set collection. Cell Syst. 2015;1:417–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Akrap N, Andersson D, Bom E, Gregersson P, Stahlberg A, Landberg G. Identification of distinct breast cancer stem cell populations based on single-cell analyses of functionally enriched stem and progenitor pools. Stem cell Rep. 2016;6:121–36.

    CAS  Google Scholar 

  30. 30.

    He DX, Xia YD, Gu XT, Jin J, Ma X. A transcription/translation-based gene signature predicts resistance to chemotherapy in breast cancer. J Pharm Biomed Anal. 2015;102:500–8.

    CAS  PubMed  Google Scholar 

  31. 31.

    Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 2005;11:1154–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8:R59.

    PubMed  PubMed Central  Google Scholar 

  33. 33.

    Duex JE, Owens C, Chauca-Diaz A, Dancik GM, Vanderlinden LA, Ghosh D, et al. Nuclear CD24 drives tumor growth and is predictive of poor patient prognosis. Cancer Res. 2017;77:4858–67.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, et al. A CD44(-)/CD24(+) phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat. 2012;133:979–95.

    CAS  PubMed  Google Scholar 

  35. 35.

    Wang Z, Wang Q, Wang Q, Wang Y, Chen J. Prognostic significance of CD24 and CD44 in breast cancer: a meta-analysis. Int J Biol markers. 2017;32:e75–e82.

    CAS  PubMed  Google Scholar 

  36. 36.

    Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res/Fundam Mol Mech Mutagen. 2011;717:1–8.

    CAS  Google Scholar 

  37. 37.

    Gwak JM, Kim M, Kim HJ, Jang MH, Park SY. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance. Oncotarget. 2017;8:36305–18.

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Shen L, Qin K, Wang D, Zhang Y, Bai N, Yang S, et al. Overexpression of Oct4 suppresses the metastatic potential of breast cancer cells via Rnd1 downregulation. Biochim et Biophys Acta (BBA)—Mol Basis Dis. 2014;1842:2087–95.

    CAS  Google Scholar 

  39. 39.

    Deleidi M, Cooper O, Hargus G, Levy A, Isacson O. Oct4-induced reprogramming is required for adult brain neural stem cell differentiation into midbrain dopaminergic neurons. PLoS ONE. 2011;6:e19926.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Gril B, Palmieri D, Qian Y, Anwar T, Liewehr DJ, Steinberg SM, et al. Pazopanib inhibits the activation of PDGFRbeta-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells. Am J Pathol. 2013;182:2368–79.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Miyake A, Nakayama Y, Konishi M, Itoh N. Fgf19 regulated by Hh signaling is required for zebrafish forebrain development. Dev Biol. 2005;288:259–75.

    CAS  PubMed  Google Scholar 

  42. 42.

    Zhao X, Xu F, Dominguez NP, Xiong Y, Xiong Z, Peng H, et al. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression. Mol Carcinog. 2018;57:1616–25.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr. Shadi Qasem for providing pathology support. We acknowledge the funding support from NIH grants R01NS087169 (to H-WL), F31CA224805–01A1 (to SRS, H-WL), T32CA079448 (to SK, RLC), R01NS087169-3S1 (to H-WL, SRS), P30CA012197 (to BP; core facility), and DoD grants W81XWH-17-1-0044 (to H-WL), W81XWH-19-1-0072 (to H-WL), and BC181274 (to H-WL).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Hui-Wen Lo.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sirkisoon, S.R., Carpenter, R.L., Rimkus, T. et al. TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene 39, 64–78 (2020). https://doi.org/10.1038/s41388-019-0959-3

Download citation

Further reading

Search

Quick links